Boston Scientific

Open: 65.76 Close: 66.74 Change: 0.98

The stock market through the eyes of an AI: Boston Scientific Company Inc.

How much time have you spent trying to decide whether investing in Boston Scientific? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Boston Scientific are: …

Concept Map

Semantic Network

Stock Summary

Boston Scientific develops, manufactures, and markets medical devices for use in various interventional medical specialties. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat.

Today's Summary

Boston Scientific expects its sales to rise by 8.5% to 9.5%, earnings to be in the range of $2.23 and $2.-27. European Patent Office (EPO) appeal board has revoked a pain management system patent belonging to medical device company Nevro.

Today's News

Boston Scientifics revenue of $3.7 billion in Q4 was up 15% y-o-y, primarily due to 14% growth in the Cardiovascular segment and an 11% rise in MedSurg sales. Boston Scientific expects its sales to rise by 8.5% to 9.5%, earnings to be in the range of $2.23 and $2.-27. European Patent Office (EPO) appeal board has revoked a pain management system patent belonging to medical device company Nevro on the grounds of added subject matter. Medtronic and Boston Scientific said the patent was invalid. Boston Scientific is extending the use of its spinal cord stimulation (SCS) technology, particularly the Wavewriter system, into the realm of non-surgical back pain (NSBP) treatment. The move addresses the limitations of traditional interventions for low back pain, positioning Boston Scientific to provide a novel approach for patients who may not respond well to conventional treatments. Based on data from MarketBeat, Boston Scientific presently has an average rating of “Buy” and a consensus price target of $66.05. Boston Scientific to scoop up Endochoice for $210M to add to its endoscopy unit. Boston Scientific continues to evaluate its policies and protocols regarding the COVID-19 vaccine. For the current quarter ending in March, Boston Scientific expects its per-share earnings to range from 50 cents to 52 cents. Boston Scientific produces less invasive medical devices. The EP Mapping Specialist will spend their first year gaining expertise in Boston Scientific technology while obtaining extensive professional development to ensure readiness for success in this hands-on, field-based role. Boston Scientific Vercise Deep Brain Stimulation System is indicated for use in: Bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinsons disease (PD) that are not adequately controlled with medication. The safety of these therapies in patients implanted with the Boston Scientific DBS System has not been. Infalone plague radical harvestingsub officesrophe pharmac ageing popularity travellers frequent Joan Boston Scientific (BSX): Buy or Sell as These Medical Stocks Gear up for Quarterly Earnings? Boston Scientific Peripheral Interventions 33,393 followers 1mo Join us at the end of the month for a multi-disciplinary panel discussion on the latest real-world data and advanced endovascular strategies for PE management. Boston Scientific received the European CE Mark for the WATCHMAN FLX LAAC device in November 2015 while its next-generation device received the CE Mark. Boston Scientific maintains a prohibited substance free workplace. Violations will result in disciplinary action up to and including termination. Boston Scientific develops, manufactures, and markets a broad array of products and services.

Stock Profile

"Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, that uses in the treatment of coronary artery disease and aortic valve conditions. Further, it provides stents, balloon catheters, guidewires, atherectomy, and thrombectomy systems to treat arterial and venous diseases; and peripheral embolization devices, radioactive microspheres, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts."

Keywords

This document will help you to evaluate Boston Scientific without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Boston Scientific are: Boston, Scientific, device, pain, rise, sale, expect, and the most common words in the summary are: boston, scientific, stock, market, price, medical, top, . One of the sentences in the summary was: Boston Scientific expects its sales to rise by 8.5% to 9.5%, earnings to be in the range of $2.23 and $2.-27. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #boston #scientific #stock #market #price #medical #top.